RHDV2 vaccine

The RHDV2 vaccine provides essential protection against Rabbit Hemorrhagic Disease Virus Type 2, a highly lethal viral pathogen that emerged in France in 2010 and has since spread globally to become the dominant RHD strain in many regions. Also known as RHDVb or Lagovirus GI.2, this virus poses a severe threat to both domestic and wild rabbit populations with mortality rates ranging from 50 to nearly 100 percent in unvaccinated animals. Unlike classical RHDV1, which primarily affected adult European rabbits, RHDV2 has a broader host range and can infect wild cottontails, hares, and other lagomorphs in addition to domestic rabbits of all ages.

The RHDV2 vaccine works by presenting the viral VP60 capsid protein to the rabbit's immune system, stimulating production of neutralizing antibodies without exposing the animal to live virus. Modern RHDV2 vaccines typically use recombinant technology, where the VP60 protein is produced using baculovirus expression systems or similar platforms rather than requiring propagation of the actual pathogen. This manufacturing approach is both safer and more efficient than traditional killed-virus vaccines. Following vaccination, the immune system recognizes the VP60 protein as foreign and mounts a defensive response, creating immunological memory that enables rapid neutralization of the actual virus upon subsequent exposure.

In the United States, the Medgene Labs RHDV2 vaccine has received USDA conditional licensure and represents the primary domestic option for protecting pet rabbits against this devastating disease. This vaccine is administered as a two-dose primary series with injections given approximately 21 days apart, followed by annual booster doses to maintain protective immunity. European rabbit owners have access to additional options including Eravac, Filavac, and the newer YURVAC RHD vaccine, some of which provide protection against multiple strains or diseases in combination formulations.

Vaccination against RHDV2 is strongly recommended for all pet rabbits in regions where the disease has been documented. In North America, RHDV2 was first detected in 2018 and has since spread to numerous states, affecting both domestic and wild rabbit populations. The virus spreads through direct contact with infected animals, contaminated materials, insect vectors, and environmental persistence, making biosecurity alone insufficient for complete protection. Only through vaccination can rabbit owners provide their pets with reliable defense against this otherwise untreatable and frequently fatal disease.

The primary indication for RHDV2 vaccination is prevention of Rabbit Hemorrhagic Disease caused by RHDV2 strains in domestic rabbits. This vaccination has become critically important since RHDV2 emerged as a global threat to rabbit populations, demonstrating higher transmissibility and a broader host range than classical RHDV1. In North America, RHDV2 has spread extensively since its 2018 introduction, establishing endemic presence in wild rabbit populations across multiple states and posing ongoing risk to unvaccinated domestic rabbits regardless of whether they live indoors or outdoors.

All pet rabbits should be considered candidates for RHDV2 vaccination, regardless of their living situation. While outdoor rabbits face direct exposure risk from contaminated environments and potential contact with wild rabbits, indoor rabbits are not immune to infection. The virus can be transmitted on clothing, shoes, equipment, hands, and even insects that enter the home. Fresh produce, hay, and plant materials from outdoor sources can potentially carry viral contamination. Given the near-universal mortality in unvaccinated exposed rabbits and the complete lack of treatment options once clinical disease develops, preventive vaccination represents the only reliable protective measure.

Rabbit rescues, shelters, and breeding facilities should implement comprehensive RHDV2 vaccination protocols for all animals in their care. These environments handle rabbits from diverse sources with unknown exposure histories, creating conditions where viral introduction could rapidly devastate entire populations. Vaccination of incoming animals during quarantine periods provides essential protection against disease establishment. Similarly, rabbits attending shows, exhibitions, or boarding facilities encounter animals from multiple sources and face elevated transmission risk, making current vaccination status essential before participation.

Veterinary practices in affected areas may recommend RHDV2 vaccination as part of routine preventive care for rabbit patients. While not all veterinarians carry rabbit vaccines, the increasing prevalence of RHDV2 has prompted many practices to add this service to protect their rabbit-owning clients. Some areas host community vaccination clinics organized by rabbit rescue organizations, veterinary schools, or animal welfare groups, providing accessible vaccination opportunities for rabbit owners who might otherwise have difficulty obtaining this protection for their pets.

Rabbits traveling to areas with documented RHDV2 presence should receive vaccination before travel if not already protected. This includes both domestic travel within affected regions and international movement where import requirements may mandate proof of vaccination. The two-dose primary series requires approximately five weeks to complete, including time for immunity to develop after the second dose, so rabbit owners should plan vaccination well in advance of anticipated travel or exposure situations.

RHDV2 vaccine administration requires veterinary involvement and cannot be performed by rabbit owners at home. The vaccine is classified as veterinarian-administered only, ensuring proper storage, handling, reconstitution if necessary, and injection technique. Rabbit owners seeking RHDV2 vaccination for their pets should contact veterinary practices experienced in rabbit medicine to schedule appropriate appointments, as not all veterinary clinics maintain rabbit vaccine inventory.

The Medgene Labs RHDV2 vaccine approved in the United States follows a two-dose primary vaccination protocol. The initial dose is administered subcutaneously, typically in the scruff area or between the shoulder blades. A second dose is given approximately 21 days later to complete the primary series and establish robust immunity. This two-dose requirement differs from some European products and reflects the specific immunization protocol established during the vaccine's development and approval process. Maximum protective immunity develops approximately two weeks after the second dose is administered.

Following completion of the primary two-dose series, annual booster vaccinations are required to maintain protective immunity against RHDV2. Some veterinarians in high-risk areas may recommend boosters every nine months rather than annually, particularly during active disease outbreaks or when local epidemiological conditions suggest heightened risk. The booster dose is a single injection that restimulates the immune memory established by the primary series. Rabbit owners should maintain accurate vaccination records and schedule booster appointments before the previous vaccination expires to ensure continuous protection.

Rabbits must meet minimum age requirements before receiving RHDV2 vaccination. The Medgene vaccine is authorized for rabbits at least seven weeks of age, though some protocols recommend waiting until eight to ten weeks for optimal immune response. Very young kits may retain maternal antibodies from vaccinated does that can interfere with vaccine response, and their developing immune systems may not produce durable protection. Rabbits below minimum vaccination age should be protected through environmental biosecurity measures while waiting to reach appropriate age.

The vaccination procedure itself involves brief but careful restraint of the rabbit while the veterinarian or veterinary technician administers the subcutaneous injection. Proper handling technique is essential as rabbits can injure themselves if they struggle or kick during restraint. The injection site should be clean and dry, and the vaccine should be at appropriate temperature before administration. Following injection, the rabbit may be observed briefly for any immediate adverse reactions before being released to their owner.

Rabbit owners should receive written documentation of vaccination including the product administered, lot number, date of each dose, and scheduled date for the next required vaccination. This documentation serves as proof of vaccination for boarding facilities, shows, or travel requirements, and enables accurate tracking of the rabbit's preventive care history. Some veterinary clinics provide vaccination reminder services to help owners maintain their rabbits' vaccination schedules.

RHDV2 vaccines have demonstrated an excellent safety profile in both clinical trials and widespread field use, with most rabbits experiencing no adverse effects or only mild, transient reactions following vaccination. The most commonly reported side effect is localized swelling or a small firm nodule at the injection site, which typically develops within a few days of vaccination and resolves spontaneously over one to two weeks. This local tissue reaction represents a normal immune response to the vaccine antigens and does not indicate a serious problem or vaccine failure.

Mild systemic effects occur in some rabbits during the first 24 to 48 hours following RHDV2 vaccination. These may include slight lethargy, reduced appetite, and decreased activity as the immune system responds to the vaccine. Such reactions are generally self-limiting and resolve without treatment within one to two days. However, rabbit owners should monitor their pets closely during this period, as prolonged appetite reduction can trigger gastrointestinal stasis, a serious condition in rabbits. Any rabbit that completely stops eating for more than 12 hours following vaccination should receive veterinary attention promptly.

Moderate reactions to RHDV2 vaccination are uncommon but may include more pronounced injection site swelling, mild fever, or behavioral changes lasting several days. Some rabbits may show reduced fecal output or changes in cecotrope production during this period as their system adjusts. Injection site reactions that continue enlarging after the first few days, become hot or painful to touch, or show signs of abscess formation warrant veterinary evaluation. While uncommon, localized infections can occur at any injection site and require appropriate treatment.

Serious adverse reactions to RHDV2 vaccines are rare when the product is administered appropriately to healthy, eligible rabbits. Anaphylactic reactions, characterized by sudden collapse, respiratory distress, facial swelling, or shock occurring within minutes of injection, are extremely uncommon but represent medical emergencies requiring immediate veterinary intervention. Veterinary clinics typically observe animals briefly following vaccination specifically to identify and address any immediate severe reactions. Death directly attributable to vaccination is exceptionally rare and typically associated with underlying health conditions or improper vaccine administration.

Rabbit owners should report any adverse reactions to their veterinarian, who may submit reports to appropriate regulatory authorities monitoring vaccine safety. Maintaining records of any post-vaccination reactions, even mild ones, helps inform future vaccination decisions for that individual rabbit. Rabbits that experience moderate or severe reactions may require modified vaccination protocols, additional monitoring during future vaccinations, or evaluation for underlying conditions that might predispose them to adverse reactions.

RHDV2 vaccination is contraindicated in rabbits with known hypersensitivity or previous severe adverse reactions to the vaccine or its components. Any rabbit that experienced anaphylaxis, severe injection site reactions, or other serious adverse events following a previous dose should not receive subsequent vaccinations with the same product without thorough veterinary evaluation and appropriate precautions. Alternative vaccine products from different manufacturers may be considered for such individuals if available in the region.

Sick or debilitated rabbits should not receive RHDV2 vaccination until their health status improves. The immune system of an ill rabbit may be compromised and unable to mount an adequate protective response to vaccination. Additionally, the physiological stress of vaccination could potentially worsen existing illness. Rabbits with active infections, fever, significant weight loss, or other signs of systemic disease should have vaccination postponed until they have recovered. However, in emergency outbreak situations, veterinarians may weigh the risk of disease exposure against the potential complications of vaccinating a mildly ill animal.

Pregnant does present special considerations for RHDV2 vaccination. While some rabbit vaccines are labeled as safe during pregnancy, data on RHDV2 vaccines in pregnant rabbits may be limited. The decision to vaccinate pregnant rabbits should be made on a case-by-case basis considering the disease risk in the area, stage of pregnancy, and the specific vaccine product's safety profile. Generally, it is preferable to ensure breeding does are fully vaccinated before breeding rather than during pregnancy. Nursing does can typically be vaccinated if disease risk is significant, though any potential effects on milk production should be monitored.

Rabbits below the minimum age specified for the vaccine product should not be vaccinated. For the Medgene RHDV2 vaccine, this minimum is seven weeks of age. Younger kits may have maternally-derived antibodies that interfere with vaccine response, resulting in inadequate protection despite receiving the vaccine. Their immature immune systems may also fail to develop durable immunity. Kits from vaccinated does receive some passive protection through maternal antibodies during their first weeks of life, providing limited coverage until they reach vaccination age. During this vulnerable period, strict biosecurity measures are essential to protect unvaccinated young rabbits.

RHDV2 vaccine interactions with other vaccines and medications require careful consideration to optimize immune responses while avoiding potential complications. When multiple vaccines are needed, such as both RHDV1 and RHDV2 protection in areas where both strains circulate, the vaccines should generally be administered at separate sites and ideally separated by two to three weeks unless combination products designed for simultaneous administration are available. This spacing allows the immune system to respond fully to each vaccine without potential interference.

Immunosuppressive medications significantly impact the effectiveness of RHDV2 vaccination. Corticosteroids, used in rabbits for various inflammatory and immune-mediated conditions, can suppress the immune response and reduce antibody production following vaccination. Rabbits receiving corticosteroid therapy should ideally complete treatment and allow recovery time before vaccination. If vaccination cannot be safely postponed due to high disease risk, the veterinarian may recommend additional booster doses or serological testing after vaccination to verify adequate immunity developed despite immunosuppressive therapy.

Antibiotics do not directly interfere with RHDV2 vaccine efficacy, and concurrent antibiotic therapy is not an absolute contraindication to vaccination. However, rabbits requiring antibiotics are typically ill, and the underlying infection may itself compromise immune response to vaccination. The veterinarian will assess whether the rabbit's condition permits vaccination or if postponement until recovery is more appropriate. When vaccination proceeds during antibiotic therapy, monitoring for adequate immune response may be warranted. Importantly, only rabbit-safe antibiotics should ever be used, as many common antibiotics are fatal to rabbits and this concern extends to any medication a rabbit receives regardless of vaccination status.

Rabbit owners should inform their veterinarian of all medications, supplements, and treatments their rabbit is currently receiving before scheduling RHDV2 vaccination. This includes prescription medications, over-the-counter products, herbal supplements, and any other substances being administered. Probiotics, commonly used to support rabbit digestive health, do not interfere with vaccination and may even support overall health during the immune response period. However, complete disclosure allows the veterinarian to identify any potential concerns and optimize the vaccination timing and protocol for the individual rabbit.

RHDV2 vaccination requires proper vaccine handling and storage to ensure product efficacy. Vaccines must be maintained under refrigeration at temperatures between 2 and 8 degrees Celsius and protected from freezing and light exposure. Improper storage can compromise vaccine potency, potentially leaving vaccinated rabbits unprotected despite receiving the injection. Veterinary practices should maintain cold chain protocols and verify vaccine integrity before administration. Rabbit owners seeking vaccination should choose established veterinary practices with experience in rabbit medicine and proper vaccine storage facilities.

Vaccination does not provide immediate protection against RHDV2. The immune system requires approximately two weeks after completing the full vaccination series to develop protective antibody levels. For the two-dose Medgene vaccine, this means approximately five weeks from the first dose until full immunity develops. During this window, rabbits remain susceptible to infection and should be protected through strict biosecurity measures. Rabbit owners should not assume their pet is protected immediately after vaccination and should maintain precautions until immunity has fully developed.

RHDV2 vaccines do not provide cross-protection against classical RHDV1, and vice versa. In regions where both viral types circulate, rabbits require vaccination against each strain separately using appropriate products. Rabbit owners should discuss the local disease epidemiology with their veterinarian to determine which vaccines are necessary for comprehensive protection. Combination vaccines covering multiple strains or diseases may be available in some regions and can simplify vaccination protocols while ensuring broad protection.

Proper handling and restraint during vaccination is essential to prevent injury to both rabbits and handlers. Rabbits can injure their spines through powerful kicking if improperly restrained, and frightened rabbits may struggle violently. Veterinary staff experienced in rabbit handling understand the need for gentle, supportive restraint that minimizes stress while maintaining adequate control. Rabbit owners can help by choosing veterinary practices with rabbit experience and by keeping their pets calm before and during the vaccination appointment.

Post-vaccination monitoring allows early detection of any adverse reactions. Rabbit owners should observe their pets closely for 24 to 48 hours following vaccination, watching for signs including lethargy, appetite loss, injection site swelling, or behavioral changes. While serious reactions are uncommon, prompt veterinary attention should be sought if concerning symptoms develop. Maintaining accurate vaccination records and noting any reactions helps inform future veterinary care and vaccination decisions for the individual rabbit.

RHDV2 vaccines require refrigerated storage at temperatures between 2 and 8 degrees Celsius to maintain potency and effectiveness. Exposure to temperatures outside this range, whether through freezing or excessive warmth, can irreversibly damage the vaccine and render it ineffective. Veterinary practices must maintain dedicated vaccine refrigerators with reliable temperature control and monitoring systems. Temperature logs should be kept to document appropriate storage conditions, and any temperature excursions should prompt evaluation of affected vaccine inventory.

Once reconstituted or opened, RHDV2 vaccine vials must be used within the timeframe specified by the manufacturer, typically within several hours. The Medgene vaccine is supplied in multi-dose vials that should be used promptly after initial entry. Some studies have examined extended use periods under strict aseptic conditions, but standard practice requires using opened vials within the labeled timeframe. Veterinary practices may coordinate vaccination clinics to maximize efficient use of multi-dose vials while ensuring each rabbit receives fresh, properly handled vaccine.

Proper disposal of vaccine materials follows standard veterinary waste protocols. Used needles and syringes must be placed in approved sharps containers, and empty or partially used vaccine vials should be disposed of according to pharmaceutical waste regulations. Vaccines should never be discarded in regular trash or poured down drains. Veterinary practices maintain established protocols for proper pharmaceutical waste handling that ensure compliance with environmental and safety regulations while protecting against potential exposure to vaccine components.

RHDV2 vaccination is appropriate and recommended for all domestic rabbit breeds without exception. Susceptibility to Rabbit Hemorrhagic Disease Virus Type 2 does not vary significantly between breeds, and unvaccinated rabbits of any breed face similarly devastating consequences upon exposure. The vaccine provides equivalent protection across the full spectrum of rabbit breeds, from tiny Netherland Dwarfs to massive Flemish Giants, and from common pet breeds to rare heritage varieties.

Dwarf breeds including Netherland Dwarfs, Holland Lops, Mini Rex, Lionheads, and other small varieties require gentle handling during vaccination procedures due to their diminutive size and often more reactive temperaments. These breeds may experience more visible injection site reactions simply because any swelling is more noticeable on their smaller frames. The standard vaccine dose remains appropriate regardless of breed size, as immune response depends on antigen quantity rather than body weight. Veterinarians experienced with small breed rabbits understand the handling modifications necessary to minimize stress during vaccination.

Giant breeds such as Flemish Giants, Continental Giants, French Lops, and other large varieties present handling challenges related to their size and strength rather than any vaccine-specific concerns. These powerful rabbits require secure restraint to prevent injury from kicking during the vaccination procedure. Despite their larger body mass, giant breeds receive the same vaccine dose as smaller rabbits. Their robust constitution may result in somewhat faster resolution of any injection site reactions compared to smaller breeds, though this varies by individual.

Lop-eared breeds, Rex varieties, Angora breeds, and other rabbits with distinctive physical characteristics all respond appropriately to RHDV2 vaccination. Long-coated breeds may benefit from fur parting at the injection site to ensure proper vaccine delivery and allow monitoring of any local reactions. Senior rabbits of any breed should maintain consistent vaccination schedules, as aging immune systems may be somewhat less robust in response to both vaccination and natural infection. Young rabbits of all breeds must reach the minimum vaccination age of seven weeks before receiving their first dose to ensure adequate immune response.

The RHDV1 vaccine represents the most directly related immunization to the RHDV2 vaccine, targeting the classical Type 1 strain of Rabbit Hemorrhagic Disease Virus. While both vaccines protect against forms of RHD, they target distinct viral genotypes and do not provide cross-protection. In regions where both RHDV1 and RHDV2 circulate, rabbits require vaccination against each strain separately. RHDV2 has become the dominant strain in most areas, but RHDV1 remains present in some populations, and comprehensive protection may require both vaccines depending on local epidemiology.

Combination vaccines available in Europe provide protection against multiple rabbit diseases in single products. Nobivac Myxo-RHD Plus protects against myxomatosis, RHDV1, and RHDV2 in one vaccination. YURVAC RHD, introduced more recently, targets RHDV2 and has been developed to address newer viral variants. Filavac and Eravac are additional European products providing RHDV protection. These combination and single-antigen vaccines offer various options for rabbit owners and veterinarians depending on regional availability, disease prevalence, and individual animal needs. In the United States, the Medgene RHDV2 vaccine remains the primary domestic option under USDA conditional license.

Myxomatosis vaccines, while protecting against an entirely different viral disease, are often discussed alongside RHD vaccines as both conditions represent major threats to rabbit health in endemic areas. Myxomatosis is caused by the Myxoma virus and produces different clinical presentations than RHD, but both diseases have high mortality rates in unvaccinated populations. In areas where both diseases occur, comprehensive vaccination protocols should address all relevant threats. Rabbit owners should consult with rabbit-savvy veterinarians to determine which vaccines are appropriate based on local disease presence, available products, and their individual rabbit's risk factors and health status.